

44
0300
#3

PATENT

Case Docket No. GENENT.074A
Date: April 3, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :	Chuntharapai et al.)	I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on
Appl. No. :	10/044,896))
Filed :	January 9, 2002)	April 3, 2002 (Date)
For :	ANTI-INTERFERON- α ANTIBODIES)	Ginger R. Dreger, Reg. No. 33,055
Examiner :	Unknown)	
Group Art Unit :	Unknown)	

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 99 references which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GENENT.074A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Chuntharapai et al.)	Group Art Unit Unknown
)	
App. No.	:	10/044,896)	
)	
Filed	:	January 9, 2002)	
)	
For	:	ANTI-INTERFERON- α)	
		ANTIBODIES)	
)	
Examiner	:	Unknown)	

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 99 references that are also enclosed. This Information Disclosure Statement is being filed within three months of the filing date of this application or upon filing if this is a CPA or RCE, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 13, 2002

By: Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 9, 2002	GROUP Unknown




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,902,618	2/20/1990	Berg	435	172.2	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	2.	EP 0139 676 B1	08.16.84	EP			
	3.	GB 1 160 544 A	12.24.85	UK			
	4.	GB 2 195 342 A	4.7.88	UK			
	5.	WO 84/03105	8.16/84	PCT			
	6.	WO 97/41229	11.6.98	PCT			
	7.	WO 99/64461	12.16.99	PCT			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	8.	Adolf et al., "Production of Monoclonal Antibodies to human IFN- α and Their Use For Analysis of the Antigenic Composition of Various Natural Interferon" <i>Journal of Cellular Physiology Supplement</i> 2:61-68 (1982)
	9.	Aquet et al., "A crystalline synthetic peptide representing the epitope of a monoclonal antibody raised against synthetic interferon- α 1 fragment 111-116" <i>Eur. J. Biochem.</i> 146:689-691 (1985)
	10.	Alexenko et al. "The Antiproliferative and Antiviral Activities of IFN- τ Variants in Human Cells" <i>Journal of Interferon and Cytokine Research</i> 17:767-779 (1997)
	11.	Alkan and Braun, "Epitope mapping of human recombinant interferon alpha molecules by monoclonal antibodies" <i>Ciba Found Symp</i> (Netherlands) 119:264-278 (1986)
	12.	Andersson et al., "Application of Four Anti-Human Interferon- α Monoclonal Antibodies for Immunoassay and Comparative Analysis of Natural Interferon Mixtures" <i>Journal of Interferon Research</i> 11:53-60 (1991)
	13.	Ansell, Philip R.J. "Hybridoma technology: a view from the patent arena" <i>Immunology Today</i> 21(8):357-358 (August 2000)
	14.	Bach, Jean Francois, "Insulin -Dependent Diabetes Mellitus as an Autoimmune Disease" <i>Endocrine Reviews</i> 15(4):516-542 (1994)
	15.	Baldeon et al., "interferon- α and interferon- γ differentially affect pancreatic β -cell phenotype and function" <i>American Physiological Society</i> C25-C32(199
	16.	Batteux et al., "FCyRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus" <i>Eur. Cytokine Netw.</i> , 10(4):50-513 (December 1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 9, 2002	GROUP Unknown



17. Beilharz, Manfred W. "Therapeutic potential for orally administered type I interferons" PSIT 3(6):193-197 (June 2000)
18. Berg, Kurt, "Identification, Production, and Characterization of Murine Monoclonal Antibody (LO-22) Recognizing 12 Native Species of Human Alpha Interferon" Journal of Interferon Research 4:481-491 (1984)
19. Bogdan, Christian "The function of type I Interferons in antimicrobial immunity" Current Opinion in Immunology 12:419-424 (2000)
20. Borrebaeck, Carl A.K. "Antibodies in diagnostics-from immunoassays to protein chips" Immunology Today 21(8):379-357 (August 2000)
21. Brod et al. "Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice" Diabetologia 41:1227-1232 (1998)
22. Brod, Staley A., "Autoimmunity Is a Type I Interferon-Deficiency Syndrome Corrected by Ingested Type I IFN via the GALT System" Journal of Interferon and Cytokine Research 10:841-852 (1999)
23. Campbell et al., "Essential Role of Interferon- γ and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice" J. Clin. Invest. 87:739- (February 1991)
24. Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy" Proc. Natl. Acad. Sci. USA 89:4285-4289 (May 1992)
25. Castano and Eisenbarth, "Type-I Diabetes: A chronic Autoimmune Disease of Human, Mouse, and Rat" Annu. Rev. Immunol. 8:647-679 (1990)
26. Chakrabarti et al. "Control of Islet Intercellular Adhesion Molecule-1 Expression by Interferon- α and Hypoxia" Diabetes 45:1336-1343 (October 1996)
27. Chakrabarti et al., "IFN- α Induces Autoimmune T Cells Through the Induction of Intracellular Adhesion Molecule-1 and B7.2" Journal of Immunology 0022-1767:522-528 (1996)
28. Chehadeh et al., "Increased Level of Interferon- α in Blood of Patients with Insulin-Dependent Diabetes Mellitus: Relationship with Coxsackievirus B Infection" Journal of Infectious Diseases 181:1929-1939 (2000)
29. Clark, Mark :Antibody Humanization: a case of the 'Emperor's new clothes'?" Immunology Today 21(8):397-401 (August 2000)
30. Clothia et al., "Conformations of immunoglobulin hypervariable regions", Nature 342:877-883 (December 1989)
31. Dall'Acqua and Carter "Antibody engineering" Current Opinion in Structural Biology 8:443-450 (1998)
32. Eaton et al., "Construction and Characterization of an Active Factor VIII Variant Lacking the Central Obne-Third of the Molecule" Biochemistry 25(26):84 8347 9December 1986)
33. Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of Key Role of Vh Residues 50 to 65" Proteins: Structure, Function , and Genetics 18:49-62 (1994)
34. Exley et al., "A Comparison of the Neutralizing Properties of Monoclonal and Polyclonal Antibodies to Human Interferon Alpha" J. Gen. Virol. 65:2277-2 (1984)
35. Fabris et al., "Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis" Journal of Hepatology 28:514-517(1998)
36. Fouli et al., "Immunoreactive α -interferon in Insulin-Secreting β Cells in TYPE 1 Diabetes Mellitus" The Lancet 1423-1427 (December 19, 1987)
37. Garcia-Porrúa et al., "Simultaneous development of SLE-like syndrome and auto-immune thyroids following α -interferon treatment" Letters to Editor 107 108
38. Glennie and Johnson "Clinical trials of antibody therapy" Immunology Today 21(8):403-410 (August 2000)
39. Gorman et al., "transient Production of Protein Using an Adenovirus Transformed Cell Line" (2) (November 1, 1990)
40. Gresser, Ion, "Wherefore interferon?", Journal of Leukocyte Biology 61:567-574 (Mary 1997)
41. Heim, Markus H. 'The jak-STAT Pathway: Cytokine Signalling from the Receptor to the Nucleus" J. of Receptor & Signal Transduction Research 19(104):75-120 (1999)
42. Hoogenboom and Chames "Natural and designed binding sites made by phage display technology" Immunology Today 21(8):371-378 (August 2000)
43. Hooks et al., "Multiple Interferons in the Circulation of Patients with Systemic Lupus Erythematosus and Vasculitis" Arthritis and Rheumatism, 25(4):39 400 (April 1982)
44. Horton et al., "Antitumor Effects of Interferon- ω : In Vivo Therapy of Human Tumor Xenografts in Nude Mice" Cancer Research 59:4064-4068 (August 1
45. Horvath et al., "A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain" Genes & Development 9:98 994 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		MAILING DATE January 9, 2002	GROUP Unknnow



46.	Huang et al., 'Interferon Expression in the Pancreases of Patients With Type I Diabetes" <u>Diabetes</u> 44:658-664 June 1995)
47.	Huang et al., "Islet Expression of Interderon-a Precedes Diabetes in Both the BB Rat and Streptozotocin-Treated Mice" <u>Immunity</u> 1:469-478 (September 1994)
48.	Hudson, Peter J. 'Recombinant antibody constructs in cancer therapy" <u>Current Opinion in Immunology</u> 11:548-557 (1999)
49.	John et al., " Isolation and Characterization of a New Mutant Human Cell Line Unresponsive to Alpha and Beta Interferons" <u>Molecular and Cellular Biology</u> 11(8):4189-4195 (August 1991)
50.	Kabat, et al. "Sequences of Proteins of Immunological Interest" Fifth Edition <u>U.S. Department of Health and Human Services Publication No. 91-3243</u> (1
51.	Kanayama et al., "Serum levels of interferon in patients with systemic lupus erythematosus" <u>Clin. Exp. Immunol.</u> 70:562-569 (1987)
52.	Kandfer-Szerszen and Lungren "Three Separate Epitopes on Human IFN- α Variants Defined by Monoclonal Antibodies and Their Role in the Binding to Receptors" <u>Archivum Immunologiae et Therapae Experimentalis</u> 40:241-246 (1992)
53.	Kay et al., "The Beta Cell in Autoimmune Diabetes: Many Mechanisms and Pathways of Loss" <u>TEM</u> 11(1):11-15 (2000)
54.	Kontsek et al., 'Antigenic Link Between Human Interferons- α and - β : The Common Epitope 1" <u>Journal of Interferon Research</u> 10:119-128 (1999)
55.	Kudela et al., "Conformational Changes in Ph2-Treated Human Interferon-Alpha 2 Detected with Monoclonal Antibodies" <u>HYBRODOMA</u> 15(3):185-189 (November 1996)
56.	Kunkel, Thomas A., 'Rapid and efficient site-specific mutagenesis without phenotype selection" <u>Proc. Natl. Acad. Sci. USA</u> 82:488-492 (January 1985)
57.	Kurabayashi et al., "Doxorubicin-Induced Id2A Gene Transcription Is Targeted at an Activation Transcription Factor/Cyclic AMP Response Element Mot through Novel Mechanisms Involving Protein Kinases Distinct from Protein Kinase C and Protein Kinase A" <u>Molecular and Cellular Biology</u> 14(11):638-6397 (Nov. 1995)
58.	Lacki et al., "Cytokine concentration in serum of Lupus erythematosus patients: the effect on acute phase response" <u>Journal of Medicine</u> 28 Nos. 1 & 2 , pp.99-107(1997)
59.	Lau et al., "Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors" <u>PNAS</u> 97(13):7278-7283 (June 2000)
60.	Laurent et al., "Purification of the Major Species of Human Leucocyte Interferon With the Help of a Monoclonal Antibody" <u>Dev. Biol. Stand.</u> (Switzerland) 57:305-310 (1984)
61.	Lefevre et al. "Interferon-delta: The first member of a novel type I interferon family" <u>Biochimie</u> 80:779-788 (1998)
62.	Little et al., "Of mice and men: hybridoma and recombinant antibodies" <u>Immunology Today</u> 21(8):364-370 (August 2000)
63.	Lydon et al., Immunochemical Mapping of α -2 Interferon" <u>Biochemistry</u> 24:4131-4141 (1985)
64.	Mannel et al., "A rat monoclonal antibody against mouse α and β interferon of all molecular weight species" <u>Nature</u> 296:664-665 (April 1982)
65.	Matsumoto et al., "Activation of the Transcription Factor ISGF3 by Interferon- γ " <u>Biol. Chem.</u> 380:699-703 (June 1998)
66.	McKendry et al., "High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both α and γ interferons" <u>Proc. Natl. Acad. Sci. USA</u> 88:11455-11459 (December 1991)
67.	Meager, Anthony "Natural Autoantibodies to Interferons" <u>Journal of Interferon and Cytokine Research</u> 17 SUP 1:S51-S53 (1997)
68.	Meager and Berg, "Editope Localization of a Monoclonal Antibody, LO-22, With Broad Specificity for Interferon- α Subtypes" <u>Journal of Interferon Research</u> 6:729-736 (1986)
69.	Milstein, Cesar 'With the benefit of hindsight" <u>Immunology Today</u> 21(8):359-364 (August 2000)
70.	Noll et al., "Production and characterization of four monoclonal antibodies specific for human interferon-alpha1 and alpha-2" <u>Biomed. Biocim. Acta</u> 48(1):165-176 (1989)
71.	Novak et al., "Preparation and Characterization of Hybridomas Producing Monoclonal Antibodies Against Human Alpha Interferon" <u>Acta Virol.</u> 30:P228-2 (1986)
72.	Oshерoff et al., "Monoclonal Antibodies to a Recombinant Human Leukocyte Interferon (IFN- α B)" <u>Clinical Immunology and Immunopathology</u> 30:188-1 (1984)
73.	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>The Journal of Immunology</u> 151:2623-2632 (September 1, 1993)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.074A	APPLICATION NO. 10/044,896
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Chuntarapai et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE January 9, 2002	GROUP Unknnow

APR 09 2002
JC58

74.	Rabinovitch, Alex, "An Update on Cytokines in the Pathogenesis of Insulin-dependent Diabetes Mellitus" <u>Diabetes/Metabolism Reviews</u> 14:129-151 (1998)
75.	Reichert, Janice M. "New biopharmaceuticals in the USA: Trends in development and marketign approvals 1995-1999" <u>TIBTECH</u> 18:364-369 (September 2000)
76.	Rhodes et al., "Effect of Human lymphoblastoid interferon on insulin synthesis and secretion in isolated human pancreatic islets" <u>Diabetologia</u> 27:601-60 (1984)
77.	Robak et al., "Association of Interferon γ , Tumor Necrosis Factor α and Interleukin 6 Serum Levels with Systemic Lupus Erythematosus Activity" <u>Aechiv Immunologi Therapiw Experimentalis</u> 46:375-380 (1998)
78.	Roberts et al., "The Evolution of the Type I Interferons" <u>Journal of Interferon and Cytokine Research</u> 18:805-816 (1998)
79.	Ronnblom et al., "Case Report, Possible induction of systemic lupus erythematosus by interferon- α treatment in a patient with a malignant carcinoid tumour" <u>Journal of Internal Medicine</u> 227:207-210 (1990)
80.	Sattayasai et al., "Universal Antibodies to Human Interferon- α Subtypes-The Production of Antipeptide Antibodies to Conserved Regions of Interferon- α " <u>Journal of Interferon Research</u> 11:41-48 (1991)
81.	Shearer et al., "Monoclonal Antibodies that Distinguish Between Subspecies of Human Interferon- α and that Detect Interferon Oligomers" <u>The Journal of Immunology</u> 133(6):3096-3101 (December 1984)
82.	Shehadan and Lafferty, "The rile of T-cells in the development of autoimmune diabetes" <u>Diabetes Reviews</u> 1(2):141-151 (1993)
83.	Shiozawa et al., "Interferon-Alpha in Lupus Psychosis" <u>Arthritis and Rheumatism</u> 35(4):417-422 (April 1992)
84.	Shou-Nee et al., "Serum interferon in systemic lupus erythematosus" <u>Bristish Journal of Dermatology</u> 117:155-159 (1987)
85.	Sobel and Ahvazi, " α -Interferon Inhibits the Development of Diabetes in NOD Mice" <u>Diabetes</u> 47:1867-1872 (December 1998)
86.	Sobel et al. "Alpha Interferon Administration Paradoxically Inhibits the Development of Diabetes in BB Rats" <u>Life Sciences</u> 62(15):1293-1302 (1998)
87.	Somoza et al., "Pancreas in Recent Onset Insulin-Dependent Diabetes Mellitus" <u>The Journal of Immunology</u> 136:1-1377 (1994)
88.	Staehelein et al., "Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons" <u>Proc. Natl. Acad. Sci. USA</u> 78(3):1848-1852 (March 1981)
89.	Stewart et al. "Induction of Type I Diabeted by Interferon- α in Transgenic Mice" <u>Science</u> 260:1942-1946 (Jun 1993)
90.	Tanaka-Kataoka et al. "Oral Use of Interferon- α Delays the Onset of Insulin-Dependent Diabetes Mellitus in Nonobese Diabetes Mice" <u>Journal of Interferon and Cytokine Research</u> 19:877-879 (1999)
91.	Tramontano et al., "Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the Vh Domains of Immunoglobulins" <u>J. Mol. Biol.</u> 215:175-182 (1990)
92.	Tsukui et al. , "A monoclonal Antibody with Broad Reactivity to Human Interferon- α Subtypes Useful for Purification of Leukocyte-Derived Interferon" <u>Microbiol. Immunol.</u> 30(11):1129-1139 (1986)
93.	Visconti et al., "Antigenic Characterization of Recombinant Lymphoblastois and Leukocyte IFN- α by Monoclonal Antibodies" <u>Journal of Interferon and Cytokine Research</u> 19:3190-326 (1999)
94.	Waguri et al., "Occurrence of IDDM during interferon therapy for chronic viral hepatitis" <u>Diabetes Research and Clinical Practice</u> 23:33-36 (1994)
95.	Wathelet et al., "Virus Infection Induces the Assembly of Coordinately Activated Transcription Factors on the IFN- β Enhancer In Vivo" <u>Molecular Cell</u> 1:5 518 (March 1998)
96.	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>The Journal of Immunology</u> 4986-4995 (1996)
97.	Wussow et al., "Presence of interferon and anti-interferon in patients with systemic lupus erythematosus" <u>Rheumatol. Int.</u> 8:225-230 (1988)
98.	Xiang et al., "Framework Residues 71 and 93 of the Chimeric B72.3 Antibody are Major Determinants of the Conformation of Heavy-chain Hypervariabl Loops" <u>J. Mol. Biol.</u> 253:385-390 (1995)
99.	Ytterberg and Schnitzer, "Serum Interferon Levels in Patients with Systemic Lupus Erythematosus" <u>Arthritis and Rheumatism</u> , 25(4):401-406 (April 1982)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364-370, XP004215163 ISSN: 0167-5699 the whole document -----	1-54
A	ANONYMOUS: "Human interferon alpha subtypes" DIAGNOSTIC RESEARCH INC., 'Online! February 1999 (1999-02), XP002222363 Retrieved from the Internet: <URL: http://www.researchd.com/cytokines/ifnasubt.htm > 'retrieved on 2002-11-25! the whole document -----	1-54

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/13	C07K16/24	C12N5/20	A61K39/395	G01N33/577
G01N33/68		A61P37/06		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EPO-Internal, CHEM ABS Data, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 885 166 A (GRUETTER MARKUS G ET AL) 5 December 1989 (1989-12-05) column 16, line 48-column 17, line 6; column 18, lines 12-23; column 19, lines 10-3; examples ----	1-54
X	US 4 902 618 A (BERG KURT F) 20 February 1990 (1990-02-20) column 3, line 64-column 4, line 49; examples ----	1-54 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 November 2002

Date of mailing of the international search report

11/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Renggli, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1999 (1999-03) SEIFARTH C ET AL: "Augmented immune response to islet cell antigens and development of diabetes mellitus under treatment with interferon-alpha in chronic hepatitis C." Database accession no. PREV199900278161 XP002222364 abstract & ZEITSCHRIFT FUER GASTROENTEROLOGIE, vol. 37, no. 3, March 1999 (1999-03), pages 235-239, ISSN: 0044-2771</p> <p>---</p> <p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996 OKANOUE TAKESHI ET AL: "Side effects of high-dose interferon therapy for chronic hepatitis C." Database accession no. PREV199699251234 XP002222368 abstract & JOURNAL OF HEPATOLOGY, vol. 25, no. 3, 1996, pages 283-291, ISSN: 0168-8278</p> <p>---</p> <p>DATABASE MEDLINE 'Online! February 1998 (1998-02) JONES T H ET AL: "Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha." Database accession no. NLM9482541 XP002222365 abstract & SEMINARS IN ONCOLOGY. UNITED STATES FEB 1998, vol. 25, no. 1 Suppl 1, February 1998 (1998-02), pages 54-63, ISSN: 0093-7754</p> <p>---</p> <p>US 6 180 370 B1 (QUEEN CARY L ET AL) 30 January 2001 (2001-01-30) the whole document</p> <p>---</p> <p>WO 96 34096 A (CELL GENESYS INC) 31 October 1996 (1996-10-31) the whole document</p> <p>---</p>	1-54
Y		1-54
Y		1-54
Y		1-54
		-/-